A randomized, double-blind, placebo-controlled Phase 2 trial of avelumab in combination with EP-101 STEMVAC in women with breast cancer
Latest Information Update: 18 May 2017
Price :
$35 *
At a glance
- Drugs Avelumab (Primary) ; EP 101-EpiThany (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 18 May 2017 New trial record
- 10 May 2017 This trial is expected to begin in the first quarter of 2018, according to an EpiThany media release.